Delisting risk
VYNE Therapeutics (VYNE)
Develops BET inhibitor therapies for inflammatory and immune-mediated diseases.
$28.56
At close0.00 (0.00%)
Something off on this page? Send us feedback.
EPSReportedEstimate
Mar '25May '25Aug '25Aug '25Nov '25Mar '26May '26May '26
Reported−$0.28−$0.20−$6.50−$0.13−$0.17−$0.10−$32.50−$0.08
Estimate−$12.50−$0.29−$11.50−$0.23−$0.19−$10.00−$9.00−$0.18
Surprise+97.8%+31.0%+43.5%+43.5%+10.5%+99.0%−261.1%+55.6%
RevenueReportedEstimate
Mar '25May '25Aug '25Aug '25Nov '25Mar '26May '26May '26
Reported$84.0K$202.0K$69.0K$69.0K$169.0K$130.0K$86.0K$86.0K
Estimate$150.0K$50.0K$150.0K$200.0K$125.0K$175.0K$200.0K$200.0K
Surprise−44.0%+304.0%−54.0%−65.5%+35.2%−25.7%−57.0%−57.0%
History
| Date | Estimate | Reported | Surprise |
|---|---|---|---|
| Aug 2026 | −$0.18 | — | — |
| May 2026 | −$0.18 | −$0.08 | +55.6% |
| May 2026 | −$9.00 | −$32.50 | −261.1% |
| Mar 2026 | −$10.00 | −$0.10 | +99.0% |
| Nov 2025 | −$0.19 | −$0.17 | +10.5% |
The latest year is open to everyone — the 40 quarters behind it read with an account. Sign in | |||
| Aug 2025 | |||
| Aug 2025 | |||
| May 2025 | |||
| Mar 2025 | |||
| Nov 2024 | |||
| Nov 2024 | |||
| Aug 2024 | |||
| May 2024 | |||
| Mar 2024 | |||
| Feb 2024 | |||
| Nov 2023 | |||
| Aug 2023 | |||
| Aug 2023 | |||
| May 2023 | |||
| Mar 2023 | |||
| Nov 2022 | |||
| Aug 2022 | |||
| May 2022 | |||
| Mar 2022 | |||
| Nov 2021 | |||
| Aug 2021 | |||
| May 2021 | |||
| Mar 2021 | |||
| Nov 2020 | |||
| Aug 2020 | |||
| May 2020 | |||
| Mar 2020 | |||
| Oct 2019 | |||
| Aug 2019 | |||
| May 2019 | |||
| Feb 2019 | |||
| Nov 2018 | |||
| Aug 2018 | |||
| May 2018 | |||
| Mar 2018 | |||
| Jan 2018 | |||
| Jun 2017 | |||
| Mar 2017 | |||
| Dec 2016 | |||
| Sep 2016 | |||
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Reaction |
|---|---|---|---|---|---|---|---|
| Aug 13, 2026 | −$0.18 | — | — | $200.0K | — | — | — |
| May 15, 2026 | −$0.18 | −$0.08 | +55.6% | $200.0K | $86.0K | −57.0% | +1.0% |
| May 14, 2026 | −$9.00 | −$32.50 | −261.1% | $200.0K | $86.0K | −57.0% | −0.1% |
| Mar 12, 2026 | −$10.00 | −$0.10 | +99.0% | $175.0K | $130.0K | −25.7% | +0.7% |
| Nov 6, 2025 | −$0.19 | −$0.17 | +10.5% | $125.0K | $169.0K | +35.2% | −0.3% |
The latest year is open to everyone — the 40 quarters behind it read with an account. Sign in | |||||||
| Aug 14, 2025 | |||||||
| Aug 13, 2025 | |||||||
| May 8, 2025 | |||||||
| Mar 6, 2025 | |||||||
| Nov 11, 2024 | |||||||
| Nov 7, 2024 | |||||||
| Aug 14, 2024 | |||||||
| May 9, 2024 | |||||||
| Mar 14, 2024 | |||||||
| Feb 29, 2024 | |||||||
| Nov 13, 2023 | |||||||
| Aug 14, 2023 | |||||||
| Aug 11, 2023 | |||||||
| May 11, 2023 | |||||||
| Mar 9, 2023 | |||||||
| Nov 10, 2022 | |||||||
| Aug 12, 2022 | |||||||
| May 12, 2022 | |||||||
| Mar 17, 2022 | |||||||
| Nov 10, 2021 | |||||||
| Aug 12, 2021 | |||||||
| May 6, 2021 | |||||||
| Mar 4, 2021 | |||||||
| Nov 5, 2020 | |||||||
| Aug 6, 2020 | |||||||
| May 11, 2020 | |||||||
| Mar 3, 2020 | |||||||
| Oct 31, 2019 | |||||||
| Aug 1, 2019 | |||||||
| May 2, 2019 | |||||||
| Feb 27, 2019 | |||||||
| Nov 7, 2018 | |||||||
| Aug 1, 2018 | |||||||
| May 9, 2018 | |||||||
| Mar 28, 2018 | |||||||
| Jan 26, 2018 | |||||||
| Jun 30, 2017 | |||||||
| Mar 31, 2017 | |||||||
| Dec 31, 2016 | |||||||
| Sep 30, 2016 | |||||||